Weekly Health Industry Report: Shanghai Biopharma M&A Fund Acquires Kanghua Bio; Saint Bella Lists on HKEX

Shanghai Biomedical M&A Fund Takes Action, Strategic Acquisition of Kangh Bio

On the evening of July 20, Kanghua Bio (Kangh) announced that Shanghai Wankexin Biotechnology Partnership (Limited Partnership) ("Wankexin Bio"), under the Shanghai Bio-Pharmaceutical M&A Fund, will acquire Kanghua Bio through a contractual agreement. In the future, both parties will accelerate Kanghua Bio’s product iteration in the vaccine field by integrating R&D resources, complementing technologies, and leveraging funding and talent, laying a foundation for the company’s long-term development. (Source: Sina Finance)

Shengbela Officially Listed on HKEX

Recently, Saint Bella, known as the "Hermès" of confinement centers, officially listed on the Hong Kong Stock Exchange. On its first day of trading, the stock surged 33.74%, with its market value skyrocketing to HK$5.366 billion at its peak. Just a day after Saint Bella's IPO, Jingze Biotech formally submitted its prospectus to the Hong Kong Stock Exchange. This biopharmaceutical company, which focuses on two major fields—assisted reproductive and ophthalmic drugs—currently has eight drug candidates in its pipeline. Among them, JZB30, a recombinant human follicle-stimulating hormone lyophilized powder injection, has been approved and is about to enter commercialization. Additionally, JZB33 (recombinant human follicle-stimulating hormone aqueous injection) and JZB05 (anti-VEGF intravitreal injection) are currently in the NDA and Phase III clinical stages, respectively, with their market launches imminent. (Source: Sina Finance)

BrioHealth Solutions and Shenqi Medical Reach Strategic Cooperation

Recently, BrioHealth Solutions (hereinafter referred to as "BrioHealth") and Shanghai Shenqi Medical Technology Co., Ltd. (hereinafter referred to as "Shenqi Medical") announced a strategic partnership. The two parties will integrate their respective advantageous resources to promote the upgrading of advanced heart failure diagnosis and treatment service systems through a product portfolio of "artificial heart + ultrafiltration technology." They aim to build solutions covering early intervention to end-stage support, providing heart failure patients with more comprehensive and precise treatment options. (Source: Arterial Network)

Leads Biolabs Launches IPO and Begins Bookbuilding

Leads Biolabs Launches Hong Kong IPO, Plans to List on July 25, Becoming the First Stock in China's TCE Field. The company focuses on novel cancer therapies and has multiple drug candidates, with its core product LBL-024 currently being evaluated for efficacy in treating various solid tumors. Funds raised from the IPO will primarily be used for clinical development, advancing preclinical assets, and enhancing production capabilities. (Source: Sina Finance)

Yantai Lannacheng Biotechnology Co., Ltd. Completes Over "300 Million Yuan" in C+ Round Financing

Dongcheng Pharmaceutical (002675.SZ) announced on July 18, 2025, that its controlling subsidiary, Yantai Lannacheng Biotechnology Co., Ltd. ("Lannacheng"), has completed a C+ round of financing exceeding "RMB 300 million." This round of financing was jointly invested by China Cinda, New Momentum Fund, and Dongcheng Pharmaceutical (002675.SZ), with Heryue Capital serving as the exclusive financial advisor. The funds raised will be mainly used to accelerate the global clinical development and industrialization process of the "diagnosis and treatment integration" innovative radiopharmaceutical conjugates (RDC) pipeline, further consolidating Lannacheng's leading position in the nuclear medicine field. (Source: Arterial Network)

ROB Completes Tens of Millions in New Financing

ROB (Shenzhen ROB Medical Technology Co., Ltd.) has recently completed a strategic financing round worth tens of millions of yuan. This round was led by the Yuanchang Fund under Fenglei Capital, with participation from existing shareholder Taikun Fund, while MB Capital served as the exclusive financial advisor. The funds will primarily be used to accelerate the R&D iteration of the intelligent surgical robot product portfolio, expand into global markets, and attract top-tier talent, marking a crucial step for the company on the path to localizing high-end medical equipment in China. (Source: Arterial Network)

Southern Prime Biotech Completes Tens of Millions of Yuan in Series A Financing

On July 16, 2025, Nanjing Southern Biotech Co., Ltd. ("Southern Biotech"), an innovative medical device company, announced today the completion of a multi-million yuan Series A financing round. This round was led by Fosun Healthcare Capital with participation from Hotang Ventures. The funds will primarily be used for the registration applications and industrialization layout of its core product — the revolutionary biopolymer hemostatic material Hemoadhican® (HD) series medical devices — with the China National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA). (Source: Arterial Network)

KaiCi Healthcare Completes Millions of Yuan in Financing

Chongqing Kaimag Medical Technology Co., Ltd. ("Kaimag Medical" for short) has recently completed a financing round worth several million yuan. This round of financing was jointly invested by Chongqing Science and Technology Financial Service Center, Chongqing Mingyue Lake Private Equity Investment Fund, and Mingyue Lake Intelligent Technology Development Co., Ltd. This investment also marks the first joint investment cooperation among the three institutions. (Source: Arterial Network)